Conference Track

Management of HBV, Advanced Liver Disease, and Other Related Complications

Source: CCO Official Conference Coverage of the 2009 Annual Meeting of the American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries A2ALL Interim Analysis: Virologic Response 12 Weeks After Liver Transplantation Feasible With Pretransplantation Peginterferon alfa-2b/Ribavirin Therapy Interim Analysis: Sorafenib Plus DEB-TACE for Patients With Unresectable HCC Shows Acceptable Toxicity Profile and Potential Efficacy Survival Benefit With Corticosteroid Plus N-Acetyl Cysteine vs Corticosteroid Alone at 2 but not 6 Months in Patients With Severe Acute Alcoholic Hepatitis HCC Risk Remains High Following at Least 12 Months of Antiviral Therapy in Cirrhotic Patients With Chronic Hepatitis B Patient and Graft Survival Lower Among HCV/HIV-Coinfected vs HCV-Monoinfected Liver Transplantation Recipients, but Incidence of Severe Posttransplantation Recurrence of HCV Disease Similar Fixed-Dose Tenofovir/Emtricitabine Safe and Effective Option for the Treatment of Patients With Chronic Hepatitis B Infection and Decompensated Liver Disease Rifaximin Provides Durable Reduction in Risk of Breakthrough Hepatic Encephalopathy in Patients With Cirrhosis Low Survival Rate in Patients With Hepatorenal Syndrome Type 1 Treated With Vasoconstrictors Plus Albumin Entecavir Associated With High Response Rates Over 36 Months in Patients With HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B Intrahepatic cccDNA Levels at End of Treatment With Peginterferon alfa-2a Plus Adefovir Predictive of SVR in Patients With Chronic Hepatitis B

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.